Abstracts tagged "Drug toxicity"

Abstract Number: 0980 • ACR Convergence 2022
The Effect and Outcomes of HCQ Alone and in Combination with Anti-Depressants on QTc
Kourtney Rudzinski¹, Zaina Shahid², Yasin kanakrieh², Saloni Goyal², Kyle Shaak² and James Ross³, ¹Lehigh Valley Health Network, Tatamy, PA, ²Lehigh Valley Health Network, Allentown, PA, ³lvhn, Macungie, PA
Background/Purpose: Hydroxychloroquine (HCQ) has faced increased scrutiny during the COVID pandemic for its association with QTc prolongation. In our field, patients are commonly on antidepressant…
Abstract Number: 1076 • ACR Convergence 2022
ANCA-Associated Vasculitis Treated with Avacopan versus a Standard Prednisone Taper: Glucocorticoid Toxicity Index Scores by Domain
Naomi Patel¹, David Jayne², Peter Merkel³, Pirow Bekker⁴, yuqing zhang⁵, Huibin Yue⁴ and John Stone⁶, ¹Massachusetts General Hospital, Sale Creek, TN, ²University of Cambridge, Cambridge, United Kingdom, ³University of Pennsylvania, Philadelphia, PA, ⁴ChemoCentryx, San Juan Capistrano, CA, ⁵Massachusetts General Hospital, Quincy, MA, ⁶Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: The ADVOCATE trial (Jayne DRW et al, N Engl J Med, 2021) was a randomized, double-blind, controlled trial of avacopan vs prednisone in addition…
Abstract Number: 1081 • ACR Convergence 2022
Incidence of Pneumocystis Jiroveci Pneumonia in Patients with ANCA Vasculitis Initiating Therapy with Rituximab or Cyclophosphamide
Elizabeth Nettleton¹, Sebastian Sattui², Zachary Wallace³ and Mike Putman¹, ¹The Medical College of Wisconsin, Milwaukee, WI, ²University of Pittsburgh, Pittsburgh, PA, ³Massachusetts General Hospital, Boston, MA
Background/Purpose: Pneumocystis jiroveci pneumonia (PJP) is an opportunistic infection that may affect patients with ANCA vasculitis (AAV). Current guidelines conditionally recommend PJP prophylaxis for patients…
Abstract Number: 0288 • ACR Convergence 2022
Comparison of the Effect of Different Janus Kinase Inhibitors on Activation, Function and Property of NK Cells to Control Cancer Cell Lines Proliferation: An Ex Vivo and in Vitro Study
Loïc Meudec¹, Pauline Richebé¹, Juliette Pascaud², Xavier Mariette³ and Gaetane Nocturne⁴, ¹Université Paris-Saclay, AP-HP-Hôpital Bicêtre, Le Kremlin Bicêtre, France, ²Université Paris-Saclay, INSERM U1184, Le Kremlin Bicêtre, France, ³Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ⁴APHP, Le Kremlin Bicêtre, France
Background/Purpose: Janus kinase inhibitors (JAKi) are effective treatments licensed in rheumatoid arthritis (RA). Concerns about a risk of cancer may arise with JAKi as in…
Abstract Number: 1108 • ACR Convergence 2022
Abnormal Baseline Chest CT Shows Increased Risk for Immune Checkpoint Inhibitor Associated Pneumonitis
Danielle Stahlbaum¹, Renea Jablonski¹, Mary Strek² and Pankti Reid¹, ¹University of Chicago Medical Center, Chicago, IL, ²University of Chicago, Chicago, IL
Background/Purpose: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but can result in off-target toxicities known as immune-related adverse events (irAEs). With increased use of…
Abstract Number: 0291 • ACR Convergence 2022
Tofacitinib Leads to Significant Weight Gain – A Real Life Experience of 429 Patients
Naga Prabu¹, velammal petchaippan², Gayathri anand³, Aswathi kumar¹ and Saranya Ramachandiran³, ¹SAKTHI RHEUMATOLOGY CENTRE PVT LTD, Coimbatore, India, ²PSG INSTTUTE OF MEDICAL SCIENCES AND RESEARCH, Coimbatore, India, ³sakthi rheumatology centre pvt l;td, Coimbatore, India
Background/Purpose: Tofacitinib(Tofa) an oral Janus kinase inhibitor(JAK) has shown good promise in the management of rheumatoid arthritis and psoriatic arthritis. While being increasingly used in…
Abstract Number: 1131 • ACR Convergence 2022
Integrating Genome and Transcriptome-Wide Associations with Real-World Data to Assess Risk for Leukopenia in Patients Taking Azathioprine
Puran Nepal, Jacy Zanussi, Alyson Dickson, Laura Daniel, Tyne Miller-Fleming, Peter Straub, Adriana Hung, Wei-Qi Wei, Nancy Cox, Michael Stein, QiPing Feng and Cecilia Chung, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Azathioprine is used to treat several autoimmune conditions, but its use is limited by side effects. Leukopenia, a severe, potentially life-threatening side effect is…
Abstract Number: 0345 • ACR Convergence 2022
Association Between Cumulated Hydroxychloroquine in Systemic Lupus Erythematosus and Development of Cardiac Conduction Alterations: A Multiple Logistic Regression Analysis
Alba Herrero-Morant¹, Jon Zubiaur-Zamacola², Adrián Margarida-De Castro², Raquel Pérez-Barquín², Miguel Ángel González-Gay³ and Ricardo Blanco⁴, ¹Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Hydroxychloroquine (HCQ) is a widely used drug in Systemic Lupus Erythematosus (SLE). It may cause cardiac alterations which includes short term arrhythmic events (via…
Abstract Number: 1133 • ACR Convergence 2022
Ancestry, ACKR1, and Leucopenia in Patients with Systemic Lupus Erythematosus
Cecilia Chung, Gul Karakoc, Jorge Gamboa, Jonathan Mosley, Nancy Cox, Michael Stein and Vivian Kawai, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem condition that occurs more frequently in certain racial groups, particularly in populations of African ancestry. Low white…
Abstract Number: 0436 • ACR Convergence 2022
Clinical Characteristics and Outcome of ANCA-Associated Vasculitides Induced by Anti-Thyroid Drugs: A Multicenter Retrospective Cohort Study
Julien Culerrier¹, Yann Nguyen², Omer Karadag³, Sule Yasar Bilge⁴, Tuba DEMIRCI YILDIRIM⁵, Tahir Saygin Öğüt⁶, Veli Yazisiz⁶, Cemal Bes⁷, Ayse Cefle⁸, Oznur Sadioglu Cagdas⁹, Ayten Yazici⁸, Andreas Kronbichler¹⁰, David Jayne¹⁰, Alexis Regent¹¹, Vitor Teixeira¹², Sylvain Marchand-Adam¹³, PIerre Duffau¹⁴, Saskia Oro¹⁵, Baptiste Andre¹⁶, Luminita Luca¹⁷, Sarah Lechtman¹⁸, Achille Aouba¹⁹, Celine Lebas²⁰, Amélie Servettaz²¹, Amandine Dernoncourt²², Marc Ruivard²³, Anne-Marie Milesi²⁴, Vincent Poindron²⁵, Patrick Jego²⁶, Roberto Padoan²⁷, Paolo Delvino²⁸, Frédéric Vandergheynst²⁹, Christian Pagnoux³⁰, Elaine Yacyshyn³¹, Peter Lamprecht³², Oliver Flossmann³³, Xavier Puéchal¹¹ and Benjamin Terrier¹¹, ¹Université Paris Cité, Paris, France, Paris, France, ²AP-HP.Centre Universit Paris Cit Hôpital Cochin, Montmorency, France, ³Hacettepe University, Ankara, Turkey, ⁴Eskişehir Osmangazi Üniversity, Eskisehir, Turkey, ⁵Dokuz Eylul University, İzmir, Turkey, ⁶Akdeniz University, Antalya, Turkey, ⁷Bahçeşehi University, Istanbul, Turkey, ⁸Kocaeli University School of Medicine Division of Rheumatology, Kocaeli, Turkey, ⁹Kocaeli University, Kocaeli, Turkey, ¹⁰University of Cambridge, Cambridge, United Kingdom, ¹¹National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ¹²Hospital de Faro, CHUA, Lisbon, Portugal, ¹³Tours University Hospital, Tours, France, ¹⁴CHU Bordeaux, Bordeaux, France, ¹⁵Assistance Publique - Hôpitaux de Paris., Paris, France, ¹⁶Hôpital de la Timone, Marseille, Marseille, France, ¹⁷CHU de Poitiers, Poitiers, France, ¹⁸CHU Nice, Nice, France, ¹⁹Department of Internal Medicine, UR4650 PSIR, Normandie Univ, UNICAEN, CHU de Caen Normandie, Caen, France, ²⁰CHRU Lille, Lille, France, ²¹CHU Reims, Reims, France, ²²CHU Amiens - Picardie, Amiens, France, ²³Clermont Ferrand University Hospital, Clermont-Ferrand, France, ²⁴Centre hospitalier de Vichy, Vichy, France, ²⁵Immunologie clinique et médecine interne, Hôpitaux universitaires de Strasbourg, Strasbourg, France, ²⁶CHU Rennes, Paris, France, ²⁷University of Padova, Padova, Italy, ²⁸Università di Pavia, Vercelli, Italy, ²⁹Professeur de Médecine Interne et Sémiologie médicale, Directeur de la Clinique de Médecine Interne Générale, Université Libre de Bruxelles, Bruxelles, France, ³⁰Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ³¹University of Alberta, Edmonton, AB, Canada, ³²Department of Rheumatology University of Lübeck Ratzeburger Allee, Lübeck, Germany, ³³Royal Berkshire Hospital, Reading, United Kingdom
Background/Purpose: ANCA-associated vasculitides (AAV) induced by anti-thyroid drugs (ATD) is a well-known entity. However, characteristics, requirement for immunosuppressive agents and the risk of relapse remain…
Abstract Number: 1134 • ACR Convergence 2022
Genome-wide Association Study Identifies Novel Loci for Leukopenia Among TPMT and NUDT15 Normal Metabolizers Taking Azathioprine
Jacy Zanussi, Puran Nepal, Alyson Dickson, Laura Daniel, Peter Straub, Tyne Miller-Fleming, Wei-Qi Wei, Adriana Hung, Nancy Cox, Vivian Kawai, Jonathan Mosley, Michael Stein, QiPing Feng, Ge Liu, Ran Tao and Cecilia Chung, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Azathioprine is a thiopurine drug used for the treatment of several inflammatory and autoimmune conditions. However, its use is limited due to side effects,…
Abstract Number: 0461 • ACR Convergence 2022
The Effects of Daily Prednisone and Tocilizumab on Hemoglobin A1c During the Treatment of Giant Cell Arteritis
Naomi Patel¹, Veronica Tozzo², John Higgins² and John Stone³, ¹Massachusetts General Hospital, Sale Creek, TN, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: Hemoglobin A1c (HbA1c) is used clinically to estimate patients' average blood glucose over the preceding few months and is affected by glycemic as well…
Abstract Number: 1283 • ACR Convergence 2022
Frequency of Checking Creatine Kinase in Patients on Statins with Elevated Transaminase for Early Detection of Statin Induced Myopathy
ANJALI NIDHAAN, Andrei Hastings, david gonzalez, rajshri joshi, nathan gilbert and carolyn o'connor, Cleveland Clinic Akron General, Akron, OH
Background/Purpose: Some of the most commonly reported side effects of statins (widely used lipid lowering agents) are muscle injury (incidence ranging from 0.1-20% based on…
Abstract Number: 0989 • ACR Convergence 2021
Risk Factors for Hydroxychloroquine Retinopathy and Its Subtypes – Prospective Adjudication Analysis of 4,899 Incident Users
April Jorge¹, Ronald Melles², Carol Conell³, Na Lu⁴, Michael Marmor⁵, Lucy Young⁶, Natalie McCormick¹, Yuqing Zhang⁷ and Hyon K. Choi⁸, ¹Massachusetts General Hospital, Boston, MA, ²Redwood City Medical Center, Department of Ophthalmology, Kaiser Permanente Northern California, Redwood City, CA, ³Kaiser Permanente Northern California, Palo Alto, CA, ⁴Arthritis Research Canada, Vancouver, BC, Canada, ⁵Stanford University, Palo Alto, CA, ⁶Massachusetts Eye and Ear Institute, Harvard Medical School, Boston, MA, ⁷Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Harvard Medical School, Boston, MA, ⁸Massachusetts General Hospital, Lexington, MA
Background/Purpose: Hydroxychloroquine (HCQ) is a key treatment for patients with lupus and other rheumatic diseases; however, the known risk factors for HCQ retinopathy (its major…
Abstract Number: 1038 • ACR Convergence 2021
Outcomes of Hydroxychloroquine Screening for Retinopathy in a Cohort of Patients with Rheumatological Conditions
Ghazala Tehseen¹, Alexandra Chadwick², Sarah Wills² and Audrey Low², ¹Faculty of Biology, Medicine and Health. The University of Manchester, Manchester, UK, Manchester, United Kingdom, ²Rheumatology Department, Salford Royal NHS Foundation Trust, Manchester, United Kingdom
Background/Purpose: Hydroxychloroquine (HCQ) is used to treat rheumatoid arthritis (RA), connective tissue disease (CTD) and other inflammatory conditions. In 2018, the United Kingdom Royal College…

« Previous Page
1
…
4
5
6
7
8
…
10
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].